Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 10/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770596 | 0.88 | ADRB1 (0.41) | ABL1HTR2CADRB1KARS1CYP1A2 | |
| SCHEMBL23770677 | 0.86 | ABL1 (0.36) | ABL1CCNT1CDK9 | |
| SCHEMBL23770808 | 0.84 | HTR3E (0.38) | ABL1HTR2CCCNT1CDK9ADRB1 | |
| SCHEMBL19951310 | 0.82 | NMT1 (0.45) | ABL1NMT1NMT2KCNH2 | |
| SCHEMBL23770776 | 0.81 | ABL1 (0.38) | ABL1CCNT1CDK9 | |
| SCHEMBL23770615 | 0.80 | ATR (0.43) | — | |
| SCHEMBL23770583 | 0.74 | RAF1 (0.36) | ABL1 | |
| SCHEMBL19968843 | 0.74 | ABL1 (0.38) | ABL1NMT1HTR2CNMT2KCNH2 | |
| SCHEMBL23770669 | 0.73 | HTR3A (0.40) | HTR2CCCNT1CDK9KCNH2 | |
| SCHEMBL23770641 | 0.73 | ABL1 (0.41) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |